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This article is the second of a two-part CME 
series on anaemia. 
According to the World Health Organiza-
tion (WHO), anaemia is defined as a condi-
tion in which the number of red blood cells 
or their oxygen-carrying capacity is insuf-
ficient to meet physiological needs, which 
vary by age, sex, altitude, smoking, and 
pregnancy status.[1]
The causes of anaemia are divided into two 
broad categories (Fig. 1):
• Central: decreased bone marrow produc-
tion/output of red blood cells, discussed 
in part 1 of the CME series on anaemia.[2]
• Peripheral: loss or destruction of red cells 
through haemolysis, bleeding or splenic 
sequestration, which is the subject of 
discussion in this issue. 
While the two categories form a sound 
basis for diagnostic work-up, they are not 
mutually exclusive. As a rule, a good reticu-
locyte response essentially excludes bone 
marrow failure. However, a combination of 
the two categories may give mixed signals 
that could present a confusing picture. By 
way of example, uncomplicated haemolysis 
with normal bone marrow function invokes 
a brisk reticulocyte response in the initial 
stages (Fig. 1), but with time, as folate is lost 
and stores are depleted, the response is blunted 
owing to ineffective haematopoiesis.
Haemolysis
Haemolysis is defined as the premature 
destruction of red cells. The lifespan of 
normal red cells is 100 - 120 days.
Haemolysis is classified as:
• intravascular, where red cells are destroyed 
within the vascular compartment
• extravascular, where red cells are destroyed 
outside the vascular system by macrophages.
It is important to understand the patho-
physiology of the two categories of haemoly-
sis, as clinical manifestations and treatment 
principles differ in the two types (Table 1).
Intravascular haemolysis
Red cells break up within the vascular com-
partment and its contents are released into 
the circulating plasma. Free Hb tetramers 
dissociate into α/non-α dimers, which are 
small enough to filter through the glome-
rulus and pass out into the urine (haemo-
globinuria). Hb loss is accompanied by iron 
loss and may cause iron deficiency. Some 
of the filtered Hb is reabsorbed by the 
proximal tubular cell, where it is degraded, 
and the iron is packaged as haemosiderin. 
Tubular cells have a rapid turnover and these 
slough off into the urine. Haemosiderinuria 
is detected by microscopic viewing of a slide 
prepared from urine sediment. Iron present 
in tubular cells stains deep blue with the 
prussian blue iron stain. 
Folic acid and carbonic anhydrase mole-
cules are small enough to filter through the 
glomerulus and pass out into urine. A third 
of total body folic acid is stored in red cells; 
therefore, ongoing haemolysis is likely to 
cause megaloblastic anaemia secondary to 
folate loss and deficiency. Similarly, loss of 
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Table 1. Intra- v. extravascular haemolysis: medium- to long-term clinical effects
Clinical effects Intravascular haemolysis Extravascular haemolysis
Haemoglobinuria/
haemosiderinuria
Yes No
Jaundice No Yes
Substrate deficiency Iron, folic acid, zinc Folic acid
Bony abnormalities Yes, e.g. frontal bossing, 
maxillary hyperplasia
Yes, e.g. frontal bossing, 
maxillary hyperplasia
Splenomegaly Yes (medium/long-term) Yes (medium/long-term)
Gallstones Less frequent Yes
Iron overload No Yes
Leg ulcers Yes Yes
Pulmonary hypertension Common, earlier onset (from 
second decade onwards)
Less common, late onset
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carbonic anhydrase, a metallo-enzyme that 
contains zinc, could lead to zinc deficiency. 
The red cell membrane comprises a 
large meshwork of interconnected lipopro-
teins, and is therefore unable to be filtered 
through the kidneys. Massive intravascular 
haemolysis (IVH) (e.g. immediate blood 
transfusion reaction) frequently results in 
obstruction of glomerular capillaries and 
may cause pre-renal renal failure.
Extravascular haemolysis
Red cells are haemolysed within the macro-
phage and its contents released into the cyto-
sol. The haem component of Hb is enzymati-
cally transformed to bilirubin, which is then 
released into the circulation. As unconjugated 
bilirubin is water insoluble, it is bound to 
albumin and the complex is finally absorbed 
by hepatocytes, where it is conjugated and 
excreted through the biliary system. 
As there is no mechanism to release excess 
iron, it continues to accumulate over the dura-
tion of haemolysis. Folic acid is also released 
into the circulation, but much of it is lost 
through the kidneys.
HS
EVH
IVH
β-thal major
Hb H disease
Warm AIHA
Delayed BTR
SCD
G6PD def
Malaria
Cold AIHA
Immediate BTR
PNH
MAHA
Fig. 2. Examples of haemolytic conditions with varying degrees of IVH and EVH. (HS = hereditary 
spherocytosis; SCD = sickle cell disease; AIHA = autoimmune haemolytic anaemia; BTR = blood trans-
fusion reaction; MAHA = micro/macro-angiopathic haemo lytic anaemia; PNH = paroxysmal nocturnal 
haemo globinuria; G6PD def = glucose-6-phosphate dehydrogenase deficiency; thal = thalas saemia.)
Anaemia
FBC and 
dierential count
Reticulocyte count Blood smear microscopy
See Table 3 for guidance
Haemolysis
Serum haptoglobin  
level suggests haemolysis
  Indirect serum 
bilirubin   
EVH
Haemosiderinuria/
haemoglobinuria   
IVH
Normal/   MCV
Blood smear morphology 
• Oval macrocytes     serum vitamin B12 and folate
• Target cells     LFT, TFT, cholesterol
HypersplenismBleeding
Increased countDecreased count
BM failure/
inltration
Nutritional 
deciency
BM aspirate and trephine biopsy
Normal Fe studies
• Hb electrophoresis
   MCV
• Serum Fe studies and ferritin
Fe deciency
• Fe administration
• Exclude bleeding
Normal vitamin 
B12 and folate
• BM examination
  Vitamin B12/folate
• Supplementation
• Investigate cause
Family history
If chronic haemolysis, check:
• Serum folate
• Serum ferritin
Locate source 
of blood loss
Investigate cause 
of splenomegaly
Fig. 1. Algorithm depicting a diagnostic approach to anaemia. (FBC = full blood count; BM = bone marrow; TFT = thyroid function test; 
LFT = liver function test; MCV = mean cell volume; Fe = iron; EVH = extravascular haemolysis.)
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Clinical manifestations and complications of 
chronic IVH and extravascular haemolysis 
(EVH) are summarised in Table 1.
It should be noted that haemolysis is 
seldom purely intravascular or extravascular. 
In instances where both IVH and EVH exist, 
the clinical picture is determined by the 
predominant type of haemolysis. Examples 
of conditions that cause haemolysis are 
summarised in Fig. 2.
Laboratory tests for 
haemolysis
The most sensitive laboratory indicator 
of haemolysis is a decreased haptoglobin 
level. Available tests for haemolysis are sum-
marised in Table 2.
Diagnostic approach to 
haemolysis 
Clinical approach
A detailed history is essential, including 
duration and frequency of symptoms, age of 
onset, blood transfusions and family history. 
Inherited varieties generally present during 
early childhood. 
Patients with homozygous beta thalassae-
mia become progressively anaemic during 
the first few months of infancy and present 
at the age of ~3 - 6 months with severe anae-
mia. During the third trimester of pregnancy 
(~27 - 30 weeks), a switch from Hb F to Hb 
A production begins. Owing to non-func-
tioning beta globin genes, there is no beta 
globin chain expression and therefore no 
Hb A production to substitute the gradual 
decline of Hb F. This results in a gradual but 
progressive drop in Hb during the first few 
months of infancy.
Patients with sickle cell disease (SCD) 
have a unique mode of presentation. The 
hallmark of SCD is an acute pain crisis, most 
commonly affecting long bones, although 
any site/organ may be affected. Severe pain 
is experienced at the site of vaso-occlusion. 
Dactylitis (pain crisis in the bones of the 
hands and feet) is often the presenting 
symptom of SCD in early childhood.[3]
Glucose-6-phosphate dehydrogenase (G6PD) 
deficiency is inheri ted in an X-linked 
fashion and therefore typically manifests in 
males, although homozygous females are 
occasionally encountered. The haemolysis 
is most commonly episodic, following expo-
sure to oxidant compounds, e.g. antimalarial 
drugs or sulphonamides. At birth, neonatal 
jaundice is common and may require inter-
vention with ultraviolet light or exchange 
transfusion in more severe cases.
Of the red cell membrane disorders, 
hereditary spherocytosis is the most com-
mon variety. It presents with the classic triad 
of anaemia, jaundice and splenomegaly. The 
red cells are destroyed in the macrophages of 
the spleen, i.e. they undergo EVH.
In chronic haemolytic states, e.g. thalassae-
mia major or intermedia, splenomegaly and 
bony abnormalities, such as frontal bossing, 
develop at an early age and are usually a 
sequel to inadequate management or poor 
patient compliance.[4]
Laboratory approach
A full blood count, differential count, reticu-
locyte count and microscopic blood smear 
examination serve as baseline tests from 
whence further investigations are performed 
(Fig. 1). If haemolysis is suspected, it should 
be confirmed with a low haptoglobin level, 
which typically decreases during an haemo-
lytic episode. Haptoglobin is a sensitive indi-
cator of IVH and EVH. It should, however, 
be noted that haptoglobin levels may also 
decrease in liver disease (due to decreased 
synthesis) and rise in inflammatory states 
or malignancy (as it is an acute-phase reac-
tant).[5] Peripheral blood smear microscopy 
(May-Grünwald-Giemsa and reticulocyte 
preparations) often provides the diagnosis 
or additional clues for further investiga-
tion (Table 3). Reticulocytes, Heinz bodies 
and Hb H inclusions in red cells can be 
detected through microscopic examination 
of smears prepared from reticulocyte prep-
arations (peripheral blood incubated with 
brilliant cresyl blue for 20 minutes). Newer-
generation blood cell counting analysers 
have the ability to enumerate reticulocytes. 
Fragmentation 
haemolysis
Fragmentation haemolytic anaemias occur 
as a result of disturbances in blood flow, 
either in large (macroangiopathic haemoly-
sis) or small (microangiopathic haemolysis) 
blood vessels. They are characterised by 
the presence of varying numbers of red 
cell fragments in the peripheral blood and 
accompanying thrombocytopenia in micro-
angiopathic haemolysis. 
Causes of macroangiopathic haemoly-
sis include prosthetic heart valves, arterio-
venous malformations and aortic stenosis. 
The anaemia is typically not severe, and 
active management is usually not required.
Microangiopathic haemolysis is caused 
by small-vessel obstruction by microthrom-
bi, the distribution of which determines 
the organ system predominantly involved. 
Causes of microangiopathic haemolytic 
anaemia (MAHA), their associations and 
the specific clinical and laboratory derange-
ments seen with each entity are summarised 
in Table 4. Several are pregnancy associated, 
and can be difficult to differentiate in the 
peripartum setting.
Thrombotic thrombocytopenic purpura 
(TTP) is an important cause of MAHA in 
South Africa (SA), as it is relatively common 
in HIV-positive patients. It carries a high 
mortality in the event of a missed diagno-
sis (~90%),[6] but with appropriate manage-
ment survival is excellent (~80%).[7] Other 
causes include autoimmune disease, a variety 
of drugs (including clopidogrel, ticlodipine 
and quinine) and congenital deficiency of 
ADAMTS13 (a metalloproteinase that cleaves 
high molecular weight Von Willebrand factor). 
HIV remains the most common cause in SA. 
TTP is characterised by a pentad of features: 
fragmentation haemolysis, thrombocytope-
nia, fever, renal failure (usually not severe), 
and fluctuating neurological derangement 
(including confusion or psychiatric manifes-
tations, seizures and focal signs). However, all 
five features are not invariably present, and a 
presumptive diagnosis of TTP is made when 
there is MAHA and thrombocytopenia, with 
exclusion of all other causes of a thrombotic 
microangiopathy (e.g. disseminated intravas-
cular coagulation). In the developed world, 
much emphasis is placed on the importance 
of documenting ADAMTS13 levels in the 
diagnosis of TTP, where its activity is report-
edly consistently low (<10%) in congenital 
and autoimmune-mediated TTP, but normal 
or more modestly reduced in other micro-
angiopathies.[7] However, ADAMTS13 levels 
are not universally low in HIV-associated TTP, 
which places the use of this test in question in 
the SA context.[8] Furthermore, ADAMTS13 
testing is not universally available in SA, and 
it is therefore not routinely recommended.
Although the gold standard of treatment 
for TTP is plasma exchange, large-volume 
fresh frozen plasma may suffice in some 
Table 2. Tests for intra- and extravascular haemolysis
Test Intravascular haemolysis Extravascular haemolysis
Serum haptoglobin  
Plasma Hb Present Absent
Haemoglobinuria Present Absent
Haemosiderinuria Present Absent
Serum lactate dehydrogenase  
Serum unconjugated bilirubin Normal 
99       February 2017, Vol. 107, No. 2
CME
patients. Corticosteroids should also be initiated at diagnosis, and 
HIV-seropositive patients should receive concomitant combination 
antiretroviral therapy, irrespective of their CD4 count. The lactate 
dehydrogenase level and platelet count are used to monitor response 
to treatment. Importantly, TTP is a relative contraindication for 
platelet transfusion, as this may fuel the microthrombotic process. 
However, platelets should not be withheld in the event of significant 
bleeding. Patients with TTP should be referred to and managed by 
specialist haematologists.
Bleeding
Anaemia due to acute bleeding usually occurs after substantial blood 
loss and is most often encountered in patients with a bleeding dia-
thesis, or in trauma, postoperative or obstetric settings. In the hyper-
acute phase of bleeding, the anaemia is usually normocytic and nor-
mochromic. This is followed by macrocytosis due to a reticulocyte 
response that develops over 2 - 3 days. Chronic low-volume blood loss 
causes a microcytic anaemia without an elevation of the reticulocyte 
production index (RPI) (due to iron deficiency). Where the source 
of the blood loss is not obvious, the following investigations may be 
helpful: (i) stool analysis for faecal occult blood; (ii) urine dipstix and 
microscopy for haemoglobinuria and detection of red cells, respec-
tively; (iii) gynaecological review; and (iv) examination of sputum for 
iron-laden macrophages (detected in pulmonary haemosiderosis due 
to intra-alveolar bleeding).
Hypersplenism
Hypersplenism refers to an enlarged spleen with sequestration or 
destruction of blood cells, which leads to the development of anaemia 
and/or neutropenia and/or thrombocytopenia. It is characterised by a 
hypercellular bone marrow response and improvement after splenec-
tomy. There may be some degree of associated haemolysis.
Table 3. Red cell morphological characteristics and interpretation
Morphological observation Differential diagnosis Further test/s indicated
Target cells with microcytosis and/or 
hypochromia
Iron deficiency
Thalassaemia trait
Anaemia of chronic disorder
Iron studies, Hb electrophoresis
Oval macrocytes, right shift Megaloblastic anaemia Vtimain B12 and folic acid levels
Round macrocytes with target cells Possible liver disease
Hypothyroidism
Hyperlipidaemia
Liver function and thyroid function tests, 
lipid profile
Sickle cells Sickle cell disease Hb electrophoresis: to confirm presence of 
Hb S and check Hb F level
Spherocytes Hereditary spherocytosis
Warm AIHA
Gamma Coombs test: positive in 
warm AIHA
Red cell membrane analysis
Autoimmune screening
Elliptocytes Hereditary elliptocytosis Red cell membrane analysis
Severe anisopoikilocytosis, diffuse/punctate 
basophilia, red cell fragmentation
Hereditary pyropoikilocytosis 
Thalassaemia major
Red cell membrane analysis, 
Hb electrophoresis
Coarse basophilic stippling 5'PNT deficiency   
Glycolytic pathway enzyme deficiency 
Lead poisoning
Plasma lead levels, red cell 
5'PNT assay, analysis of glycolytic pathway 
enzymes 
Autoagglutination Noted in cold AIHA Non-gamma Coombs test: positive in 
cold AIHA
Red cell fragmentation Decreased platelet count → microangiopathic 
haemolysis
Normal platelet count → macroangiopathic 
haemolysis
See Table 4
Malaria Plasmodium falciparum life-threatening infection Identify species
Monitor FBC and parasite count during 
treatment
Heinz bodies (reticulocyte preparation)
Bite cells (May-Grünwald-Giemsa 
preparation)
G6PD deficiency 
Exposure to oxidant compounds 
Unstable Hb
Oxidant drug or toxin history, check red cell 
G6PD level
Hb H inclusions Present in alpha thalassaemia Hb electrophoresis, PCR for alpha 
thalassaemia
5'-PNT = 5'-pyrimidine nucleotidase; AIHA = autoimmune haemolytic anaemia; PCR = polymerase chain reaction.
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The spleen functions as a reservoir for blood cells and a filter that 
removes senescent, abnormal or antibody-coated red cells from 
the circulation. When it is enlarged, these functions are amplified; 
therefore, red cell survival is somewhat attenuated and the number 
of cells sequestered is increased. This may result in mild to moderate 
reductions in red cell, white cell and/or platelet counts, as well as 
biochemical evidence of haemolysis. 
Hypersplenism may occur in any patient with splenomegaly, 
regardless of the cause, including portal hypertension, infectious 
causes (such as chronic malaria), chronic haemolytic states, or haematolo-
gical malignancies. A peripheral blood smear review is routinely indicated 
in patients with splenomegaly, and bone marrow examination 
in instances where the cause for the splenomegaly is not readily 
apparent. 
Where anaemia is caused by hypersplenism alone, i.e. without an 
underlying cause, the red cells are usually normocytic and normo-
chromic. The reticulocyte count and RPI are usually raised, but may 
be lower than anticipated owing to sequestration of reticulocytes in 
the spleen. In patients with portal hypertension, anaemia is often 
microcytic and hypochromic because of iron deficiency from chronic 
blood loss, e.g. bleeding oesophageal varices, haematuria or gastro-
intestinal bleeding in chronic schistosomiasis. The latter is not an 
uncommon cause of portal hypertension in SA.
Conclusion
Causes of anaemia are numerous and varied. Owing to its manifesta-
tion in a wide variety of conditions, investigating the cause requires 
a thorough history, physical examination and systematic laboratory 
and ancillary investigations.
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Table 4. Summary of common microangiopathic haemolytic anaemias
Microangiopathic entity Common features Associations/risk factors Management
TTP Anaemia and thrombocytopenia
++ red cell fragmentation
+ renal impairment
Fever
Fluctuating neurological manifestations
ADAMSTS13 levels may be low
HIV infection
Autoimmune disease
Drugs (clopidogrel, ticlodipine, 
quinine)
Metastatic adenocarcinoma
Allogeneic stem cell/solid organ 
transplantation
Congenital deficiency of 
ADAMTS13 (rare)
Plasma exchange
Steroids
DIC Anaemia and thrombocytopenia
+ red cell fragments
Deranged coagulogram (INR and/or PTT, 
D-dimers, fibrinogen and AT levels)
Major trauma
Sepsis
Obstetric accidents
Treat underlying cause
FFP/cryoprecipitate infusion
LMWH*
Platelet infusion if bleeding
HUS +/++ red cell fragments
Marked renal impairment
Moderate anaemia and thrombocytopenia
Complement 3 and 4 levels may be low in 
aHUS
Shiga toxin-associated diarrhoeal 
illness
Shigella dysenteriae 
Escherichia coli (O157:H7 and 
O104:H4)
aHUS dysregulation of alternate 
C' pathway
Congenital factor H or I deficiency
Antibodies to factor H 
Supportive measures
A trial of plasma exchange 
for aHUS
Eculizumab (limited 
availability) 
Dialysis, usually for aHUS
HELLP syndrome/pre-
ecclampsia
Anaemia and thrombocytopenia
+ red cell fragments
Raised AST/ALT 
Hypertension
Headache and visual disturbance, RUQ pain, 
pulmonary oedema
Risk of recurrence in subsequent 
pregnancies
Emergency delivery by 
caesarean section
DIC = disseminated intravascular coagulation; TTP = thrombotic thrombocytopenic purpura; aHUS = atypical haemolytic uraemic syndrome; RUQ = right upper quadrant; 
INR = international normalised ratio; PTT = partial thromboplastin time; LMWH = low-molecular-weight heparin; AT = antithrombin; HELLP = haemolysis/elevated liver enzymes/
low platelet count; ++ = moderate to severe; + = mild to moderate; FFP = fresh frozen plasma; AST = aspartate transaminase; ALT = alanine transaminase; C' = complement.
*LMWH is particularly useful if thrombotic manifestations predominate.
